NNRTI interactions - HIV Guidelines

DHHS Last Updated: September 2024
Australian Commentary Last Updated: December 2024

AU Comment: Rilpivirine (RPV)

Despite there being no direct effect on RPV plasma concentration, high doses of oral supplements may modify gastric pH, thereby affecting RPV absorption – subsequent potential impact on maintenance of viral suppression.

AU Comment: Between-class ARV switching

in the context of between-class ARV switches, clinicians may need to factor in enzyme induction of some NNRTIs, time to induction dissipation, and potential impact on ARV being introduced.

Table 24b. Drug Interactions Between Non-Nucleoside Reverse Transcriptase Inhibitors and Other Drugs

This table provides information on the known or predicted interactions between non-nucleoside reverse transcriptase inhibitors (NNRTIs) and non-antiretroviral drugs. Cabotegravir (CAB) intramuscular (IM) plus rilpivirine (RPV) IM are co-packaged into a single product and are coadministered as a complete regimen; therefore, the dosing recommendations and clinical comments reflect the combination of CAB IM and RPV IM treatments. Drug interaction studies were not conducted with either CAB IM or RPV IM. Drug interaction studies with oral CAB and RPV were leveraged to make the dosing recommendations for CAB IM and RPV IM. For information regarding interactions between NNRTIs and other antiretroviral (ARV) drugs, including dosing recommendations, refer to Tables 24c, 24e, 24f, 25a, and 25b.

Recommendations for managing a particular drug interaction may differ, depending on whether a new ARV drug is being initiated in a patient on a stable concomitant medication or if a new concomitant medication is being initiated in a patient on a stable ARV regimen. The magnitude and significance of drug interactions are difficult to predict when several drugs with competing metabolic pathways are prescribed concomitantly. When an interacting drug needs to be replaced with an alternative, providers should exercise their clinical judgment to select the most appropriate alternative medication.

Oral doses of RPV at 75 mg and 300 mg once daily (equivalent to 3 and 12 times the recommended dose) were associated with prolonged QTc (or QT corrected for heart rate) interval. Known and expected/theoretical pharmacokinetic interactions, resulting in increased RPV exposures, are included in this table due to the safety concern of QTc prolongation. There is limited information about the potential for pharmacodynamic interactions between RPV (in the absence of increased RPV exposures) and drugs that prolong the QTc interval; therefore, these are not included in this table.

Nevirapine (NVP) is no longer commonly used in clinical practice in the United States and is not included in this table. Please refer to the U.S. Food and Drug Administration product labels for information regarding drug interactions between NVP and concomitant medications. Information may also be found in archived versions of this guideline.

Concomitant Drug	NNRTI	Effect on NNRTI and/or Concomitant Drug Concentrations	Dosing Recommendations and Clinical Comments
Acid Reducers
Antacids	DOR, EFV	↔ NNRTI AUC	No dose adjustment needed.
	ETR	↔ ETR expected	No dose adjustment needed.
	RPV IM	↔ RPV expected	No dose adjustment needed.
	RPV PO	↓ RPV expected when given simultaneously	Give antacids at least 2 hours before or at least 4 hours after RPV.
H2 Receptor Antagonists	DOR	↔ NNRTI expected	No dose adjustment needed.
	EFV	↔ EFV AUC	No dose adjustment needed.
	ETR	↔ ETR AUC	No dose adjustment needed.
	RPV IM	↔ RPV expected	No dose adjustment needed.
	RPV PO	RPV AUC ↓ 76% when famotidine 40 mg is taken 2 hours prior	Give H2 receptor antagonists at least 12 hours before or at least 4 hours after RPV.
Proton Pump Inhibitors	DOR	DOR AUC ↓ 17% and C_min↓ 16%	No dose adjustment needed.
	EFV	↔ EFV and NVP expected
	ETR	With Omeprazole 40 mg Daily ETR AUC ↑ 41%
	RPV IM	↔ RPV expected	No dose adjustment needed.
	RPV PO	With Omeprazole 20 mg Daily RPV AUC ↓ 40% and C_min↓ 33%	Contraindicated.
Alpha-Adrenergic Antagonists for Benign Prostatic Hyperplasia
Alfuzosin,Doxazosin, Silodosin, Terazosin	DOR, RPV IM, RPV PO	↔ alpha-adrenergic antagonists expected	No dose adjustment needed.
Alfuzosin,Doxazosin, Silodosin, Terazosin	EFV, ETR, NVP	↓ alpha-adrenergic antagonists expected	Consider alternative ARV or alpha-antagonist therapy. If coadministration is necessary, monitor for therapeutic effectiveness of alpha antagonist.
Tamsulosin	DOR, RPV IM, RPV PO	↔ tamsulosin expected	No dose adjustment needed.
Tamsulosin	EFV, ETR, NVP	↓ tamsulosin expected	Monitor for therapeutic effectiveness of tamsulosin after 2–4 weeks. May need to increase dose to tamsulosin 0.8 mg once daily for patients who fail to respond to the 0.4-mg dose.
Antibacterials—Antimycobacterials
Bedaquiline	DOR, RPV IM, RPV PO	↔ bedaquiline expected	No dose adjustment needed.
Bedaquiline	EFV, ETR	↓ bedaquiline possible	Do not coadminister.
Rifabutin	DOR	DOR AUC ↓ 50%	Increase DOR dose to 100 mg twice daily. No dose adjustment is needed for rifabutin.
	EFV	Rifabutin ↓ 38%	The recommended dosing range is rifabutin 450–600 mg per day.
	ETR	↔ rifabutin and metabolite AUC ETR AUC ↓ 37%	Do not coadminister ETR plus PI/r with rifabutin. Use rifabutin 300 mg once daily if ETR is administered without PI/r.
	RPV IM	↓ RPV expected	Contraindicated.
	RPV PO	Rifabutin plus RPV 50 mg PO Once Daily Compared to RPV 25 mg Once Daily Alone ↔ RPV AUC and C_min	Increase RPV dose to 50 mg PO once daily. No dose adjustment for rifabutin is needed.
Rifampin	DOR	DOR AUC ↓ 88%	Contraindicated. After stopping rifampin, wait 4 weeks before initiating DOR.
	EFV	EFV AUC ↓ 26%	Do not use EFV 400 mg with rifampin. Maintain EFV dose at 600 mg once daily and monitor for virologic response.
	ETR	Significant ↓ ETR possible	Do not coadminister.
	RPV IM	↓ RPV expected	Contraindicated.
	RPV PO	RPV AUC ↓ 80%	Contraindicated.
Rifapentine	DOR	DOR 100 mg Twice Daily plus Once-Weekly Rifapentine and Isoniazid Compared to DOR 100 mg Twice Daily Alone OR AUC ↓ 29%, C_min ↓ 31%	Contraindicated. After stopping rifapentine, wait 4 weeks before initiating DOR.
	EFV	Daily Rifapentine (Max 600 mg) With EFV ↔ EFV concentrations Weekly Rifapentine (Max 900 mg) With EFV ↔ EFV concentrations	No dose adjustment needed.
	ETR	↓ ETR possible	Do not coadminister.
	RPV IM, RPV PO	↓ RPV expected	Contraindicated.
Antibacterials—Macrolides
Azithromycin	DOR, EFV, ETR, RPV IM, RPV PO	↔ azithromycin expected	No dose adjustment needed.
Clarithromycin	DOR	↔ clarithromycin expected ↑ DOR possible	Monitor for ARV tolerability if used in combination.
	EFV	Clarithromycin AUC ↓ 39%	Monitor for effectiveness, or consider alternative agent (e.g., azithromycin) for MAC prophylaxis and treatment.
	ETR	Clarithromycin AUC ↓ 39% ETR AUC ↑ 42%	Consider alternative macrolide (e.g., azithromycin) for MAC prophylaxis and treatment.
	RPV IM, RPV PO	↔ clarithromycin expected ↑ RPV possible	Consider alternative macrolide (e.g., azithromycin) for MAC prophylaxis and treatment. If coadministered, monitor for QTc prolongation.
Erythromycin	DOR	↑ DOR possible	Monitor for ARV tolerability if used in combination.
	EFV, ETR	↑ EFV, ETR, and NVP possible ↓ erythromycin possible	Monitor for ARV tolerability and antibiotic efficacy if used in combination.
	RPV IM, RPV PO	↑ RPV possible	Consider alternative macrolide (e.g., azithromycin). If coadministered, monitor for QTc prolongation.
Anticoagulants
Apixaban	DOR, RPV IM, RPV PO	↔ apixaban expected
Apixaban	EFV, ETR	↓ apixaban possible	.
Dabigatran, Edoxaban	DOR, EFV, ETR, RPV IM, RPV PO	↔ DOAC expected	No dose adjustment needed.
Rivaroxaban	DOR, RPV IM, RPV PO	↔ rivaroxaban expected	No dose adjustment needed.
Rivaroxaban	EFV, ETR	↓ rivaroxaban possible	Consider alternative ARV or anticoagulant therapy.
Warfarin	DOR, RPV IM, RPV PO	↔ warfarin expected	No dose adjustment needed.
Warfarin	EFV, ETR	↑ or ↓ warfarin possible	Monitor INR and adjust warfarin dose accordingly.
Antiseizure
Carbamazepine, Phenobarbital, Phenytoin	DOR	↓ DOR possible	Contraindicated. After stopping anticonvulsant, wait 4 weeks before initiating DOR.
	EFV	Carbamazepine plus EFV Carbamazepine AUC ↓ 27% EFV AUC ↓ 36% Phenytoin plus EFV ↓ EFV ↑ or ↓ phenytoin possible	Consider alternative ARV or anticonvulsant. If coadministration is necessary, monitor anticonvulsant and EFV concentrations.
	ETR	↓ anticonvulsant and ETR possible	Do not coadminister.
	RPV IM, RPV PO	↓ RPV possible	Contraindicated.
Eslicarbazepine	DOR, EFV, ETR, RPV IM, RPV PO	↓ NNRTI possible	Consider alternative ARV or anticonvulsant. If coadministration is necessary, monitor virologic response and consider monitoring plasma concentrations of ARVs.
Oxcarbazepine	DOR, RPV IM, RPV PO	↓ NNRTI possible	Contraindicated.
Oxcarbazepine	EFV, ETR	↓ NNRTI possible	Consider alternative ARV or anticonvulsant. If coadministration is necessary, monitor virologic response and consider monitoring plasma concentrations of ARVs.
Ethosuximide, Lacosamide, Tiagabine, Zonisamide	DOR, RPV IM, RPV PO	↔ anticonvulsant expected	No dose adjustment needed.
Ethosuximide, Lacosamide, Tiagabine, Zonisamide	EFV, ETR	↓ anticonvulsant possible	Monitor seizure control. Consider anticonvulsant therapeutic drug monitoring.
Lamotrigine	DOR, ETR, RPV IM, RPV PO	↔ lamotrigine expected	No dose adjustment needed.
Lamotrigine	EFV	↓ lamotrigine possible	Monitor seizure control and plasma concentrations of lamotrigine.
Antidepressants, Anxiolytics, and Antipsychotics Also see the Sedative/Hypnotics section below.
*Antidepressants and Anxiolytics*
Bupropion	DOR, ETR, RPV IM, RPV PO	↔ bupropion expected	No dose adjustment needed.
Bupropion	EFV	Bupropion AUC ↓ 55%	Titrate bupropion dose based on clinical response.
Citalopram, Escitalopram	DOR, RPV IM, RPV PO	↔ antidepressant expected	No dose adjustment needed.
Citalopram, Escitalopram	EFV, ETR	↓ antidepressant possible	Titrate antidepressant dose based on clinical response.
Desvenlafaxine, Venlafaxine	DOR, EFV, ETR, RPV IM, RPV PO	↔ antidepressant expected	No dose adjustment needed.
Duloxetine	DOR, EFV, ETR, RPV IM, RPV PO	↔ antidepressant expected	No dose adjustment needed.
Fluoxetine, Fluvoxamine	DOR, EFV, ETR, RPV IM, RPV PO	↔ antidepressant expected	No dose adjustment needed.
Mirtazapine	DOR, RPV IM, RPV PO	↔ mirtazapine expected	No dose adjustment needed.
Mirtazapine	EFV, ETR	↓ mirtazapine possible	Monitor antidepressant effect. Titrate dose as necessary based on clinical response.
Nefazodone	DOR, RPV IM, RPV PO	↑ NNRTI possible	No dose adjustment needed.
Nefazodone	EFV, ETR	↓ nefazodone expected ↑ NNRTI possible	Monitor antidepressant effect. Titrate dose as necessary based on clinical response.
Paroxetine	DOR, ETR, RPV IM, RPV PO	↔ paroxetine expected	No dose adjustment needed.
Paroxetine	EFV	↔ paroxetine expected	No dose adjustment needed.
Sertraline	DOR, RPV IM, RPV PO	↔ sertraline expected	No dose adjustment needed.
	EFV	Sertraline AUC ↓ 39%	Monitor the antidepressant effect. Titrate dose as necessary based on clinical response.
	ETR	↓ sertraline possible
Trazodone	DOR, RPV IM, RPV PO	↔ trazodone expected	No dose adjustment needed.
Trazodone	EFV, ETR	↓ trazodone possible	Monitor for therapeutic effectiveness of trazodone and titrate dose as necessary.
Tricyclic Antidepressants (e.g., amitriptyline, doxepin, nortriptyline)	DOR, EFV, ETR, RPV IM, RPV PO	↔ antidepressant expected	No dose adjustment needed
*Antipsychotics*
Aripiprazole	DOR, RPV IM, RPV PO	↔ aripiprazole expected	No dose adjustment needed.
Aripiprazole	EFV, ETR	↓ aripiprazole expected	Monitor for therapeutic effectiveness of antipsychotic. Consider doubling usual dose of aripiprazole over 1–2 weeks. Refer to aripiprazole prescribing information for dose recommendations.
Brexpiprazole	DOR, RPV IM, RPV PO	↔ brexpiprazole expected	No dose adjustment needed.
Brexpiprazole	EFV, ETR	↓ brexpiprazole expected	Monitor for therapeutic effectiveness of antipsychotic. Consider doubling the usual dose of brexpiprazole and making further adjustments based on clinical response. Refer to brexpiprazole prescribing information.
Cariprazine	DOR, RPV IM, RPV PO	↔ cariprazine expected	No dose adjustment needed.
Cariprazine	EFV, ETR	↓ cariprazine and ↑ or ↓ active metabolite possible	Do not coadminister.
Iloperidone	DOR, RPV IM, RPV PO	↔ antipsychotic expected	No dose adjustment needed.
Iloperidone	EFV, ETR	↓ antipsychotic possible	Monitor for therapeutic effectiveness of antipsychotic.
Lumateperone	DOR, RPV IM, RPV PO	↔ antipsychotic expected	No dose adjustment needed.
Lumateperone	EFV, ETR	↓ antipsychotic possible	Do not coadminister.
Lurasidone	DOR, RPV IM, RPV PO	↔ antipsychotic expected	No dose adjustment needed.
Lurasidone	EFV, ETR	↓ antipsychotic possible	Monitor for therapeutic effectiveness of antipsychotic.
Olanzapine, Olanzapine/Samidorphan	DOR, ETR, NVP, RPV IM, RPV PO	↔ olanzapine expected	No dose adjustment needed.
Olanzapine, Olanzapine/Samidorphan	EFV	↓ olanzapine possible	Monitor for therapeutic effectiveness of olanzapine.
Other Antipsychotics CYP3A4 substrates (e.g., clozapine, perphenazine, risperidone)	DOR, RPV IM, RPV PO	↔ antipsychotic expected	No dose adjustment needed.
	EFV, ETR	↓ antipsychotic possible	Monitor for therapeutic effectiveness of antipsychotic.
Pimavanserin	DOR, RPV IM, RPV PO	↔ pimavanserin expected	No dose adjustment needed.
Pimavanserin	EFV, ETR	↓ pimavanserin expected	Do not coadminister.
Pimozide	DOR, RPV IM, RPV PO	↔ pimozide expected	No dose adjustment needed.
Pimozide	EFV, ETR	↓ pimozide possible	Monitor for therapeutic effectiveness of pimozide.
Quetiapine	DOR, RPV IM, RPV PO	↔ antipsychotic expected	No dose adjustment needed.
Quetiapine	EFV, ETR	↓ antipsychotic possible	Monitor for therapeutic effectiveness of antipsychotic.
Ziprasidone	DOR, RPV IM, RPV PO	↔ antipsychotic expected	No dose adjustment needed.
Ziprasidone	EFV, ETR	↓ antipsychotic possible	Monitor for therapeutic effectiveness of antipsychotic.
Antifungals
Fluconazole	DOR	↑ DOR possible	No dose adjustment needed.
	EFV	↔ fluconazole expected ↔ EFV AUC	No dose adjustment needed.
	ETR	ETR AUC ↑ 86%	No dose adjustment needed.
	RPV IM, RPV PO	↑ RPV possible	No dose adjustment needed. If coadministered, consider monitoring for QTc prolongation.
Ibrexafungerp	DOR, RPV PO	↑ NNRTI possible	No dose adjustment needed.
	EFV, ETR	↓ ibrexafungerp expected ↑ NNRTI possible	No dose adjustment needed.
	RPV IM	↔ ibrexafungerp expected ↔ RPV IM expected	Do not coadminister.
Isavuconazole	DOR	↑ DOR possible	No dose adjustment needed.
	EFV, ETR	↓ isavuconazole possible	Monitor isavuconazole concentration and antifungal response. Dose adjustments for isavuconazole may be necessary.
	RPV IM, RPV PO	↑ RPV possible	No dose adjustment needed. If coadministered, consider monitoring for QTc prolongation.
Itraconazole	DOR	↑ DOR possible	No dose adjustment needed.
	EFV	EFV With Itraconazole Solution Itraconazole and OH-itraconazole AUC, C_max, and C_min ↓ 37% to 44% EFV With Itraconazole Capsules Itraconazole AUC ↓ 86% and OH-itraconazole AUC 84%	Do not coadminister unless potential benefits outweigh the risks. Failure to achieve therapeutic itraconazole concentrations has been reported. If coadministration is necessary, closely monitor itraconazole concentration and adjust dose accordingly.
	ETR	↓ itraconazole possible ↑ ETR possible	Dose adjustments for itraconazole may be necessary. Monitor itraconazole concentration and antifungal response.
	RPV IM, RPV PO	↑ RPV possible	No dose adjustment needed. If coadministered, consider monitoring for QTc prolongation.
Posaconazole	DOR, ETR	↑ NNRTI possible	No dose adjustment needed.
	EFV	Posaconazole AUC ↓ 50% ↔ EFV AUC	Do not coadminister unless potential benefits outweigh the risks. If coadministration is necessary, monitor posaconazole concentration and adjust dose accordingly.
	RPV IM, RPV PO	↑ RPV possible	No dose adjustment needed. If coadministered, consider monitoring for QTc prolongation.
Voriconazole	DOR	↑ DOR possible	No dose adjustment needed.
	EFV	Voriconazole AUC ↓ 77% EFV AUC ↑ 44%	Contraindicated at standard doses. Adjust dose to voriconazole 400 mg twice daily plus EFV 300 mg daily.
	ETR	↔ voriconazole AUC ETR AUC ↑ 36%	No dose adjustment needed.
	RPV IM, RPV PO	↑ RPV possible	No dose adjustment needed. If coadministered, consider monitoring for QTc prolongation.
Antimalarials
Artemether/Lumefantrine	DOR, RPV IM, RPV PO	↔ antimalarial expected	No dose adjustment needed.
	EFV	Artemether AUC ↓ 79% DHA AUC ↓ 75% Lumefantrine AUC ↓ 30% to 56%	Consider alternative ARV or antimalarial drug. If used in combination, monitor closely for antimalarial efficacy.
	ETR	Artemether AUC ↓ 38% ↔ DHA AUC ↔ lumefantrine AUC ↔ ETR AUC	Clinical significance of the reduced antimalarial drug concentrations is unknown. If used in combination with ETR, monitor for antimalarial efficacy.
Atovaquone/Proguanil	DOR, ETR, RPV IM, RPV PO	No data	Monitor for antimalarial efficacy.
Atovaquone/Proguanil	EFV	Atovaquone AUC ↓ 75% Proguanil AUC ↓ 43%	No dose recommendation. Consider alternative drug for malaria prophylaxis, if possible.
Antimigraine
*Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists*
Atogepant	DOR, RPV IM, RPV PO	↔ atogepant expected	No dose adjustment needed
Atogepant	EFV, ETR	↓ atogepant possible	Episodic migraine: Increase atogepant dose to 30–60 mg once daily. Chronic migraine: Do not coadminister.
Rimegepant	DOR, RPV IM, RPV PO	↔ rimegepant expected	No dose adjustment needed
Rimegepant	EFV, ETR	↓ rimegepant possible	Consider alternative ARV or migraine medication.
Ubrogepant	DOR, RPV IM, RPV PO	↔ ubrogepant expected	No dose adjustment needed
Ubrogepant	EFV, ETR	↓ ubrogepant expected	Use initial dose of 100 mg, followed by second dose of 100 mg if needed.
Zavegepant	DOR, RPV IM, RPV PO	↔ zavegepant expected	No dose adjustment needed
Zavegepant	EFV, ETR	↓ zavegepant possible	No dose adjustment needed
*Serotonin 5-HT1B, 1D Receptor Agonists*
Almotriptan, Eletriptan	DOR, RPV IM, RPV PO	↔ almotriptan expected	No dose adjustment needed
Almotriptan, Eletriptan	EFV, ETR	↓ almotriptan possible	No dose adjustment needed
Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan, Zolmitriptan	DOR, EFV, ETR, RPV IM, RPV PO	↔ migraine medication expected	No dose adjustment needed
Antiplatelets
Clopidogrel	DOR, RPV IM, RPV PO	↔ clopidogrel expected	No dose adjustment needed.
Clopidogrel	EFV, ETR	↓ activation of clopidogrel possible	Consider alternative ARV or antiplatelet. ETR may prevent metabolism of clopidogrel to its active metabolite.
Prasugrel	All NNRTIs	↔ prasugrel expected	No dose adjustment needed.
Ticagrelor	DOR, RPV IM, RPV PO	↔ ticagrelor expected	No dose adjustment needed.
Ticagrelor	EFV, ETR, NVP	↓ ticagrelor expected	Consider alternative ARV or anticoagulant therapy.
Vorapaxar	DOR, RPV IM, RPV PO	↔ vorapaxar expected	No dose adjustment needed.
Vorapaxar	EFV, ETR	↓ vorapaxar expected	Insufficient data to make a dose recommendation.
Antipneumocystis and Antitoxoplasmosis
Atovaquone (oral solution)	DOR, ETR, RPV IM, RPV PO	No data	Monitor for therapeutic effectiveness of atovaquone.
Atovaquone (oral solution)	EFV	Atovaquone AUC ↓ 44% to 47%	Consider alternative ARV or agent for PCP or toxoplasmosis treatment or prophylaxis. If coadministration is necessary, monitor for therapeutic effectiveness of atovaquone.
Antivirals—Hepatitis C
Elbasvir/Grazoprevir	DOR	↔ elbasvir and grazoprevir DOR AUC ↑ 56% and C_min↑ 41%	No dose adjustment needed.
	EFV	Elbasvir AUC ↓ 54% Grazoprevir AUC ↓ 83% ↔ EFV	Contraindicated.
	ETR	↓ elbasvir and grazoprevir expected	Do not coadminister.
	RPV IM	↔ elbasvir and grazoprevir expected ↔ RPV expected	No dose adjustment needed.
	RPV PO	↔ elbasvir and grazoprevir ↔ RPV AUC and C_min	No dose adjustment needed.
Glecaprevir/Pibrentasvir	DOR	↑ DOR expected	No dose adjustment needed.
	EFV	↓ glecaprevir and pibrentasvir expected	Do not coadminister.
	ETR	↓ glecaprevir and pibrentasvir possible	Do not coadminister.
	RPV IM	↔ glecaprevir and pibrentasvir expected ↑ RPV expected	No dose adjustment needed.
	RPV PO	↔ glecaprevir and pibrentasvir RPV AUC ↑ 84%	No dose adjustment needed.
Ledipasvir/Sofosbuvir	DOR	↔ ledipasvir and sofosbuvir ↔ DOR	No dose adjustment needed.
	EFV	Ledipasvir AUC, C_min, and C_max ↓ 34% ↔ sofosbuvir
	ETR	No significant effect expected
	RPV IM	↔ ledipasvir, sofosbuvir, and RPV expected
	RPV PO	↔ ledipasvir and sofosbuvir ↔ RPV
Sofosbuvir/Velpatasvir	DOR, RPV IM, RPV PO	No significant effect expected	No dose adjustment needed.
	EFV	Velpatasvir AUC ↓ 43%, C_max ↓ 37%, and C_min ↓ 47%	Do not coadminister.
	ETR	↓ velpatasvir expected	Do not coadminister.
Sofosbuvir/‌Velpatasvir/‌Voxilaprevir	DOR, RPV IM, RPV PO	No significant effect expected	No dose adjustment needed.
	EFV	Velpatasvir AUC ↓ 43%, C_max ↓ 37%, and C_min ↓47% ↓ voxilaprevir expected	Do not coadminister.
	ETR	↓ voxilaprevir expected ↓ velpatasvir expected	Do not coadminister.
Antivirals—Miscellaneous (e.g., for CMV, Mpox)
Brincidofovir	All NNRTIs	↔ brincidofovir expected	No dose adjustment needed.
Cidofovir	All NNRTIs	↔ cidofovir expected	No dose adjustment needed.
Maribavir	DOR RPV IM, RPV PO	↔ maribavir expected	No dose adjustment needed.
Maribavir	EFV, ETR	↓ maribavir possible	No dose adjustment needed.
Tecovirimat	DOR, RPV PO	↓ DOR or RPV expected but not likely to be clinically relevant	No dose adjustment needed.
	EFV, ETR	↔ EFV, ETR, or NVP expected	No dose adjustment needed.
	RPV IM	↓ RPV expected but not likely to be clinically relevant	No dose adjustment needed. If there is a concern for suboptimal RPV exposure, seek expert consultation. Do not initiate CAB/RPV IM during and within 2 weeks after tecovirimat treatment. (Refer to Table 24d for interaction with CAB.)
Antivirals—SARS-CoV-2
Molnupiravir	All NNRTIs	↔ expected	No dose adjustment needed
Remdesivir	All NNRTIs	↔ expected	No dose adjustment needed
Ritonavir-Boosted Nirmatrelvir	DOR	With Ritonavir 100 mg Twice Daily DOR AUC ↑ 254%	No dose adjustment needed
Ritonavir-Boosted Nirmatrelvir	EFV, ETR, RPV PO, RPV IM	↔ expected	No dose adjustment needed
Cardiac Medications
*Beta-Blockers*
Atenolol, Metoprolol, Nebivolol	DOR, EFV, ETR, RPV IM, RPV PO	↔ beta-blocker expected	No dose adjustment needed
Bisoprolol, Carvedilol	DOR, RPV IM, RPV PO	↔ beta-blocker expected	No dose adjustment needed
Bisoprolol, Carvedilol	EFV, ETR	↓ beta-blocker possible	No dose adjustment needed. Monitor blood pressure and heart rate and titrate to clinical effect.
Labetalol	DOR, RPV IM, RPV PO	↔ beta-blocker expected	No dose adjustment needed
Labetalol	EFV, ETR	↑ beta-blocker possible	No dose adjustment needed. Monitor blood pressure and heart rate and adjust dose to achieve desired clinical effect.
*Calcium Channel Blockers*
Dihydropyridine Calcium Channel Blockers (e.g., amlodipine, nifedipine)	DOR, RPV IM, RPV PO	↔ CCBs expected	No dose adjustment needed
	EFV, ETR	↓ CCBs possible	Titrate CCB dose based on clinical response.
Non-Dihydropyridine Calcium Channel Blockers (e.g., diltiazem, verapamil)	DOR, RPV IM, RPV PO	↔ CCBs expected ↑ NNRTI possible	No dose adjustment needed
	EFV	Diltiazem AUC ↓ 69% ↓ verapamil possible	Titrate diltiazem or verapamil dose based on clinical response.
	ETR	↓ diltiazem or verapamil possible
*Cardiac—Other*
Bosentan	DOR	↓ DOR possible	Consider alternative ARV or alternative to bosentan. If coadministration is necessary, monitor virologic response.
	EFV, ETR	↓ NNRTI possible ↓ bosentan possible	Consider alternative ARV or alternative to bosentan. If coadministration is necessary, monitor bosentan efficacy and virologic response.
	RPV IM, RPV PO	↓ RPV possible	Consider alternative ARV or alternative to bosentan. If coadministration is necessary, monitor virologic response.
Eplerenone	DOR, RPV IM, RPV PO	↔ eplerenone expected	No dose adjustment needed.
Eplerenone	EFV, ETR	↓ eplerenone possible	Titrate eplerenone dose based on clinical response.
Ivabradine	DOR, RPV IM, RPV PO	↔ ivabradine expected	No dose adjustment needed.
Ivabradine	EFV, ETR	↓ ivabradine expected	Contraindicated
Mavacamten	DOR, RPV IM, RPV PO	↔ mavacamten expected ↓ NNRTI possible	Consider alternative ARV or alternative to mavacamten. If coadministration is necessary, monitor virologic response.
Mavacamten	EFV, ETR	↓ mavacamten expected ↓ NNRTI possible	Contraindicated
Ranolazine	DOR, RPV IM, RPV PO	↔ ranolazine expected	No dose adjustment needed
Ranolazine	EFV, ETR	↓ ranolazine expected	Contraindicated
Corticosteroids
Beclomethasone, Ciclesonide	DOR, EFV, ETR, RPV IM, RPV PO	↔ corticosteroid expected	No dose adjustment needed
Budesonide, Fluticasone, Mometasone	DOR, RPV IM, RPV PO	↔ corticosteroid expected	No dose adjustment needed
Budesonide, Fluticasone, Mometasone	EFV, ETR	↓ corticosteroid possible	Monitor corticosteroid efficacy and titrate as needed. May consider alternative corticosteroid for long-term use.
Dexamethasone	DOR, EFV, ETR	↓ NNRTI possible	Consider alternative corticosteroid for long-term use. If dexamethasone is used with NNRTI, monitor virologic response.
Dexamethasone	RPV IM, RPV PO	Significant ↓ RPV possible	Contraindicated with more than a single dose of dexamethasone.
Prednisone, Prednisolone	DOR, RPV IM, RPV PO	↔ corticosteroid expected	No dose adjustment needed
Prednisone, Prednisolone	EFV, ETR,	↓ corticosteroid possible	Monitor corticosteroid efficacy and titrate as needed. May consider alternative corticosteroid for long-term use.
Glucose-Lowering
Linagliptin, Sitagliptin	DOR, RPV IM, RPV PO	↔ antihyperglycemic expected	No dose adjustment needed.
Linagliptin, Sitagliptin	EFV, ETR	↓ antihyperglycemic possible	Monitor glycemic control.
Metformin	DOR	↔ metformin AUC DOR AUC ↓ 26% and C_max ↓ 24%	No dose adjustment needed.
	EFV, ETR, RPV IM	↔ metformin expected	No dose adjustment needed.
	RPV PO	↔ metformin AUC	No dose adjustment needed.
Sodium-Glucose Cotransporter-2 Inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin)	DOR, EFV, ETR, RPV IM, RPV PO	↔ antihyperglycemic expected	No dose adjustment needed.
Herbal Products
St. John’s Wort	DOR	↓ DOR expected	Contraindicated. After stopping St. John’s Wort, wait 4 weeks before initiating DOR.
	EFV, ETR	↓ EFV, ETR, and NVP expected	Do not coadminister.
	RPV IM, RPV PO	↓ RPV expected	Contraindicated.
Hormonal Therapies—Contraceptives
Injectable Contraceptives Depot MPA	DOR, ETR, RPV IM, RPV PO	↔ MPA expected	No dose adjustment needed.
Injectable Contraceptives Depot MPA	EFV	↔ MPA	No dose adjustment needed. Refer to Women With HIV section for people on EFV and RIF.
Oral Contraceptives (e.g., desogestrel, drospirenone, ethinyl estradiol, levonorgestrel, norgestimate)	DOR	↔ ethinyl estradiol ↔ levonorgestrel ↔ drospirenone expected	No dose adjustment needed.
	EFV	↔ ethinyl estradiol Etonogestrel (metabolite of oral desogestrel) C_min ↓ 61% Levonorgestrel (metabolite of oral norgestimate) AUC ↓ 83% Norelgestromin (metabolite of oral norgestimate) AUC ↓ 64% ↓ drospirenone possible	When Used for Contraception Use alternative ARV or contraceptive methods. When Used for Other Clinical Indications (e.g., Acne, Menstrual Cycle Regulation) Monitor for clinical effectiveness of hormonal therapy.
	ETR	Ethinyl estradiol AUC ↑ 22% ↔ norethindrone ↓ drospirenone possible	No dose adjustment needed for regimens that do not contain drospirenone For drospirenone-containing regimens used for contraception, use alternative ARV or alternative contraceptive method. If using drospirenone for other clinical indications, monitor for clinical effectiveness of hormonal therapy.
	RPV IM	↔ ethinyl estradiol expected ↔ norethindrone expected ↔ drospirenone expected	No dose adjustment needed.
	RPV PO	↔ ethinyl estradiol ↔ norethindrone ↔ drospirenone expected	No dose adjustment needed.
Subdermal Implant Contraceptives (e.g., etonogestrel, levonorgestrel)	DOR, RPV IM, RPV PO	↔ etonogestrel expected ↔ levonorgestrel expected	No dose adjustment needed.
	EFV	Etonogestrel AUC ↓ 63% to 82% Levonorgestrel AUC ↓ 42% to 47% Levonorgestrel 300 mg Implant With 600 mg EFV Compared to Levonorgestrel 150 mg Implant Levonorgestrel AUC ↓ 34%	Use alternative ARV or contraceptive methods. Unintended pregnancies were observed in women who used EFV and levonorgestrel implant concomitantly.
	ETR	↓ etonogestrel possible ↓ levonorgestrel possible	No data available to make dose recommendation.
	ETR	↓ etonogestrel possible ↓ levonorgestrel possible	Consider using alternative ARV or contraceptive method.
Transdermal Contraceptives (e.g., ethinyl estradiol/norelgestromin, ethinyl estradiol/levonorgestrel)	DOR, RPV IM, RPV PO	↔ ethinyl estradiol or norelgestromin expected	No dose adjustment needed.
	EFV	↓ ethinyl estradiol or norelgestromin possible	Consider using alternative ARV or contraceptive method.
	ETR	↓ ethinyl estradiol or norelgestromin possible	Consider using alternative ARV or contraceptive method.
Vaginal Ring Contraceptives (e.g., etonogestrel/ethinyl estradiol, segesterone/ethinyl estradiol)	DOR, RPV IM, RPV PO	↔ etonogestrel and ethinyl estradiol expected ↓ segesterone and ethinyl estradiol expected	No dose adjustment needed.
	EFV	Ethinyl estradiol (intravaginal ring) AUC ↓ 56% Etonogestrel (intravaginal ring) AUC ↓ 81%	Use alternative ARV or contraceptive method.
	EFV	↓ segesterone and ethinyl estradiol possible	Consider alternative ARV or contraceptive method.
	ETR	↓ etonogestrel and ethinyl estradiol possible	No data available to make dose recommendation.
Emergency Contraceptives Levonorgestrel (oral)	DOR, RPV IM, RPV PO	↔ levonorgestrel expected	No dose adjustment needed.
	EFV	Levonorgestrel 1.5 mg Plus 600 mg EFV Levonorgestrel AUC ↓ 58% Levonorgestrel 3 mg Plus 600 mg EFV Compared to Levonorgestrel 1.5 mg Alone ↔ levonorgestrel AUC	Increase dose of levonorgestrel to 3mg when used for emergency postcoital contraception.
	ETR	↓ levonorgestrel possible	Consider alternative ARV or contraceptive method.
Hormonal Therapies—Gender Affirming and Menopause
Estradiol	DOR, RPV IM, RPV PO	↔ estradiol expected	No dose adjustment needed
	EFV	Estradiol AUC ↓ 28% ↔ EFV AUC	Monitor effects of estrogen and therapy. Titrate dose as necessary to achieve therapeutic goals.
	ETR	↓ estradiol possible
5-Alpha Reductase Inhibitors (e.g., dutasteride, finasteride)	DOR, RPV IM, RPV PO	↔ dutasteride and finasteride expected	No dose adjustment needed
	EFV, ETR	↓ dutasteride and finasteride possible	Monitor effects of testosterone. Titrate testosterone dose as necessary to achieve therapeutic goals.
Testosterone	DOR, RPV IM, RPV PO	↔ testosterone expected	No dose adjustment needed
Testosterone	EFV, ETR	↓ testosterone possible	Monitor effects of testosterone. Titrate testosterone dose as necessary to achieve therapeutic goals.
Other Gender-Affirming Medications	DOR, RPV IM, RPV PO	↔ hormonial concentrations expected	No dose adjustment needed
Other Gender-Affirming Medications	EFV, ETR	↓ crypterone and progestogens possible ↔ goserelin, leuprolide acetate, and spironolactone expected	Monitor feminizing effects of estrogen and antiandrogen therapy. Titrate testosterone dose as necessary to achieve therapeutic goals.
Menopausal Hormone Replacement Therapy (e.g., conjugated estrogens, drospirenone, estradiol, medroxyprogesterone, progesterone)	DOR, RPV IM, RPV PO	↔ hormonal concentrations expected	No dose adjustment needed
	EFV, ETR	↓ estrogen possible with estradiol or conjugated estrogen (equine and synthetic) ↓ medroxyprogesterone possible ↓ micronized progesterone possible ↓ drospirenone possible See Contraceptives—Oral above for other progestin-NNRTI interactions	Monitor menopausal symptoms. Titrate to the dose of hormonal therapy that achieves menopausal symptom relief.
Immunosuppressants
Cyclosporine	DOR, RPV IM, RPV PO	↔ cyclosporine expected ↑ NNRTI possible	No dose adjustment needed.
Cyclosporine	EFV, ETR	↓ cyclosporine possible	Increase in immunosuppressant dose may be necessary. Therapeutic drug monitoring of immunosuppressant is recommended. Consult with specialist as necessary.
Everolimus, Sirolimus, Tacrolimus	DOR, RPV IM, RPV PO	↔ immunosuppressant expected	No dose adjustment needed.
Everolimus, Sirolimus, Tacrolimus	EFV, ETR	↓ immunosuppressant possible	Increase in immunosuppressant dose may be necessary. Therapeutic drug monitoring of immunosuppressant is recommended. Consult with specialist as necessary.
Lipid-Modifying
Atorvastatin	DOR	↔ atorvastatin AUC	No dose adjustment needed.
	EFV, ETR	Atorvastatin AUC ↓ 32% to 43%	Adjust atorvastatin dose according to lipid response, but do not exceed the maximum recommended dose.
	RPV IM	↔ atorvastatin expected	No dose adjustment needed.
	RPV PO	↔ atorvastatin AUC	No dose adjustment needed.
Fluvastatin	DOR, RPV IM, RPV PO	↔ fluvastatin expected	No dose adjustment needed.
Fluvastatin	EFV, ETR	↑ fluvastatin possible	Dose adjustments for fluvastatin may be necessary. Monitor for fluvastatin toxicity.
Lovastatin, Simvastatin	DOR, RPV IM, RPV PO	↔ lovastatin and simvastatin expected	No dose adjustment needed.
	EFV	Simvastatin AUC ↓ 60% to 68% Simvastatin active metabolite AUC ↓ 60%	Adjust simvastatin dose according to lipid response, but do not exceed the maximum recommended dose.
	ETR	↓ lovastatin possible ↓ simvastatin possible	Adjust lovastatin or simvastatin dose according to lipid response, but do not exceed the maximum recommended dose.
Pitavastatin	DOR, ETR, RPV IM, RPV PO	↔ pitavastatin expected	No dose adjustment needed.
Pitavastatin	EFV	↔ pitavastatin AUC	No dose adjustment needed.
Pravastatin	DOR, RPV IM, RPV PO	↔ pravastatin expected	No dose adjustment needed.
	EFV	Pravastatin AUC ↓ 44%	Adjust statin dose according to lipid responses, but do not exceed the maximum recommended dose.
	ETR	↓ pravastatin possible
Rosuvastatin	DOR, EFV, ETR, RPV IM, RPV PO	↔ rosuvastatin expected	No dose adjustment needed.
Narcotics and Treatment for Opioid Dependence
Buprenorphine Sublingual or buccal	DOR, RPV IM, RPV PO	↔ buprenorphine expected	No dose adjustment needed.
	EFV	Buprenorphine AUC ↓ 50% Norbuprenorphine (active metabolite) AUC ↓ 71%	No dose adjustment needed, monitor for withdrawal symptoms.
	ETR	Buprenorphine AUC ↓ 25%	No dose adjustment needed.
Buprenorphine Implant	DOR, RPV IM, RPV PO	↔ buprenorphine expected	No dose adjustment needed.
Buprenorphine Implant	EFV, ETR	No data	Clinical monitoring is recommended when NNRTI is initiated after insertion of buprenorphine implant.
Lofexidine	DOR, EFV, ETR, RPV IM, RPV PO	↔ lofexidine expected	No dose adjustment needed.
Methadone	DOR	↔ methadone AUC DOR AUC ↓ 26%	No dose adjustment needed.
	EFV	Methadone AUC ↓ 52%	Opioid withdrawal common; monitor and increase methadone dose as necessary.
	ETR	↔ methadone AUC	No dose adjustment needed.
	RPV IM	↓ methadone AUC expected	No dose adjustment needed, but monitor for withdrawal symptoms.
	RPV PO	R-methadone^a AUC ↓ 16%	No dose adjustment needed, but monitor for withdrawal symptoms.
PDE5 Inhibitors
Avanafil, Tadalafil, Vardenafil	DOR, RPV IM, RPV PO	↔ PDE5 inhibitor expected	No dose adjustment needed.
Avanafil, Tadalafil, Vardenafil	EFV, ETR, NVP	↓ PDE5 inhibitor possible	May need to titrate dose based on clinical effect.
Sildenafil	DOR	↔ sildenafil expected	No dose adjustment needed.
	EFV	↓ sildenafil possible	May need to titrate sildenafil dose based on clinical effect.
	ETR	Sildenafil AUC ↓ 57%	May need to titrate sildenafil dose based on clinical effect.
	RPV IM	↔ sildenafil expected	No dose adjustment needed.
	RPV PO	↔ sildenafil AUC and C_max	No dose adjustment needed.
Sedative/Hypnotics
*Benzodiazepines*
Alprazolam, Triazolam	DOR, RPV IM, RPV PO	↔ alprazolam or triazolam expected	No dose adjustment needed.
Alprazolam, Triazolam	EFV, ETR	↓ alprazolam or triazolam possible	Monitor for therapeutic effectiveness of benzodiazepine.
Diazepam	DOR, RPV IM, RPV PO	↔ diazepam expected	No dose adjustment needed.
	EFV	↓ diazepam possible	Monitor for therapeutic effectiveness of diazepam.
	ETR	↑ diazepam possible	Decreased dose of diazepam may be necessary. Monitor for diazepam toxicity.
Lorazepam	DOR, ETR, RPV IM, RPV PO	↔ lorazepam expected	No dose adjustment needed.
Lorazepam	EFV	↔ lorazepam AUC	No dose adjustment needed.
Midazolam	DOR	↔ midazolam AUC	No dose adjustment needed.
	EFV	↑ or ↓ midazolam possible	Monitor for therapeutic effectiveness and toxicity of midazolam.
	ETR	Midazolam AUC ↓ 31% Midazolam active metabolite C_max ↑ 57%	Monitor for therapeutic effectiveness of midazolam.
	RPV IM, RPV PO	↔ midazolam expected	No dose adjustment needed.
*Orexin Receptor Antagonists*
Daridorexant	DOR, RPV IM, RPV PO	↔ daridorexant expected	No dose adjustment needed
	EFV	Daridorexant AUC ↓ 61%	Do not coadminister.
	ETR	↓ daridorexant possible	Do not coadminister.
Lemborexant, Suvorexant	DOR, RPV IM, RPV PO	↔ lemborexant expected	No dose adjustment needed
Lemborexant, Suvorexant	EFV, ETR	↓ lemborexant possible	Do not coadminister.
*Other Sedatives*
Eszopiclone, Zolpidem	DOR, RPV IM, RPV PO	↔ eszopiclone or zolpidem expected	No dose adjustment needed
Eszopiclone, Zolpidem	EFV, ETR	↓ eszopiclone or zolpidem possible	Monitor for therapeutic effectiveness of sedative and titrate to clinical effect.
Miscellaneous
Finerenone	DOR, RPV IM, RPV PO	↔ finerenone expected	No dose adjustment needed
Finerenone	EFV, ETR	↓ finerenone expected	Consider alternative ARV or alternative to finerenone. If coadministration is necessary, monitor finerenone efficacy.
Praziquantel	DOR, RPV IM, RPV PO	↔ praziquantel expected	No dose adjustment needed
	EFV	R-praziquantel and S-praziquantel AUC ↓ 74% to 75%	Do not coadminister. If coadministration is necessary, consider alternative ARVs.
	ETR	↓ praziquantel possible	Do not coadminister. If coadministration is necessary, consider alternative ARVs.
^aR-methadone is the active form of methadone. Key to Symbols: ↑ = increase ↓ = decrease ↔ = less than 20% change in AUC Key: ARV = antiretroviral; AUC = area under the curve; Cmax = maximum plasma concentration; Cmin = minimum plasma concentration; CAB = cabotegravir; CCB = calcium channel blocker; DAA = direct-acting antiviral; DHA = dihydroartemisinin; DOAC = direct oral anticoagulants; DOR = doravirine; EFV = efavirenz; ETR = etravirine; IM = intramuscular; INR = international normalized ratio; isoniazid = isonicotinic acid hydrazide; MAC = Mycobacterium avium complex; MPA = medroxyprogesterone acetate; CMV = cytomegalovirus; NNRTI = non-nucleoside reverse transcriptase inhibitor; OH-itraconazole = active metabolite of itraconazole; PCP = Pneumocystis jirovecii pneumonia; PDE5 = phosphodiesterase type 5; PI/r = protease inhibitor/ritonavir; PO = orally; QTc = QT corrected for heart rate; RPV = rilpivirine

Resources

Legal

About Us

Contact Us

ASHM Head Office – Sydney

Level 3, 160 Clarence Street Sydney, NSW 2000

Tel: (+61) 02 8204 0700 Fax: (+61) 02 8204 0782

Acknowledgement of Country

ASHM acknowledges the Traditional Owners of Country across the various lands on which we live and work. We recognise Aboriginal and Torres Strait Islander peoples’ continuing connection to land, water, and community and we pay our respects to Elders past and present. ASHM acknowledges Sovereignty in this country has never been ceded. It always was, and always will be, Aboriginal land.

Endorsement:

The HIV PEP guidelines have been endorsed by the Blood Borne Viruses and Sexually Transmitted Infections Standing Committee (BBVSS).

Funded by:

The Australian Centre for Disease Control.

Disclaimer:

The information provided on this website and its related websites and guidelines, and the resources made available by ASHM in any format or medium, are for general information purposes only and are not intended as medical advice or as a substitute for consultation with a qualified healthcare professional. While ASHM Health strives to provide accurate and current resources and information, the resources, information and guidelines made available by ASHM Health do not provide personalised medical advice, diagnosis, or treatment. Healthcare professionals should apply their clinical judgment and consider individual circumstances when using this information. To the extent permitted by law, ASHM Health disclaims all liability for any outcomes resulting from reliance on the information provided. For specific medical concerns, please consult a licensed healthcare provider.

Whilst the Australian Centre for Disease Control provides financial assistance to ASHM, the material contained in this resource produced by ASHM should not be taken to represent the views of the Australian Centre for Disease Control. The content of this resource is the sole responsibility of ASHM. www.ashm.org.au

Adult Antiretroviral Guidelines Guidelines

Pediatric Antiretroviral Guidelines

Anal Cancer Screening Guidelines for PLHIV

PEP Guidelines

PrEP Guidelines

HIV Testing Policy

Frequently used tools

Drug Interactions Between Non-Nucleoside Reverse Transcriptase Inhibitors and Other Drugs